Strip away the press release and here's what the therapy actually does. People with sickle cell or beta-thalassemia have defective adult hemoglobin. But everyone is born making a different, healthy version — fetal hemoglobin — that a gene called BCL11A normally switches off shortly after birth. The therapeutic idea is elegant: edit BCL11A so it can't do its job, and the body resumes making the fetal hemoglobin that masks the disease.
The patent record tells this story in two layers, and it's worth keeping them straight. The first layer is the disease-specific application. Vertex's granted patent US12644137B2, "Materials and methods for treatment of hemoglobinopathies" (issued June 2, 2026), names inventors including Vertex leadership and covers the materials and methods for editing blood stem cells to treat exactly these conditions. That is the layer closest to the approved product.
The second layer is the editing tool itself. CRISPR did not originate at Vertex; the foundational machinery traces to grants like the Broad Institute's US12644111B2 ("CRISPR enzymes and systems," issued June 2, 2026, inventor Feng Zhang) and US12644136B2, which specifically addresses delivery of CRISPR systems to hematopoietic stem cells. A therapy company building a product on CRISPR is building on top of an estate that, in part, sits with the academic institutions that pioneered the tool.
Why does this two-layer structure decide economics? Because a one-time gene-editing cure carries a very high list price, and that price has to be split across everyone with a claim on the technology. When a treatment depends on both a company's application patents and an institution's platform patents, the licensing stack — who gets paid, and how much — shapes the margin as surely as the manufacturing cost does.
The fetal-hemoglobin target itself has deep roots in the patent literature, too. The strategy of derepressing fetal hemoglobin by going after BCL11A appears in earlier grants such as US10472619B2 ("Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction," 2019). The clinical idea predates the approved product by years; the patents are the paper trail of that long runway.
Here's what the filings actually let a general reader conclude. The science is real and approved. But the economics of a CRISPR cure are not set by the biology alone — they're set by a layered patent estate spanning the company that commercialized it and the institutions that invented the underlying tool. Read the grants together and you can see why a single dose costs what it does.